Variational AI

What Variational AI does

Variational AI has developed Enki, the industry's first commercially available foundation model for small-molecule drug discovery. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers. The platform generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile, eliminating hit ID and hit-to-lead stages. This enables pharma and biotech partners to move directly into Lead Optimization with novel structures. Variational AI's approach uses generative AI to design novel, synthesizable small molecules optimized across potency, selectivity, ADMET, and synthetic feasibility, providing higher-quality leads for discovery programs. The company aims to redefine the unit economics of drug discovery for better patient outcomes.

Products

• EnkiThe industry's first commercially available foundation model for small-molecule drug discovery. It generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile, moving beyond fixed screening libraries to explore uncharted regions of chemical space. Enki is purpose-built for the earliest stages of small molecule drug discovery, generating first- and best-in-class compounds for 873 pre-trained drug targets.

Key capabilities

• Generative AI platform for early-stage drug discovery
• Generates optimized, synthesis-ready, lead-like compounds
• Eliminates hit ID and hit-to-lead stages
• Enables direct movement into Lead Optimization
• Designs novel, synthesizable small molecules
• Optimizes across potency, selectivity, ADMET, and synthetic feasibility
• Generates novel molecular structures de novo
• Multiparameter optimization across 50+ parameters (potency, selectivity, toxicity, ADMET, PK, synthetic accessibility)

Use cases

• Early-stage small molecule drug discovery
• Generating first-in-class compounds
• Generating best-in-class compounds
• Hit generation
• Lead optimization
• Unlocking new chemical space
• Accelerating the path to novel therapies

AI approach

Variational AI has developed Enki, the industry's first commercially available foundation model for small-molecule drug discovery. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers. The platform generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile, eliminating hit ID and hit-to-lead stages. It generates novel molecular structures de novo and simultaneously optimizes across 50+ parameters including potency, selectivity, toxicity, ADMET, PK, and synthetic accessibility.

Tech named: generative AI, machine learning, foundation model

Industries served

• Biotechnology Research
• Pharmaceutical
• Biopharma

What it says sets it apart

• Industry's first commercially available foundation model for small-molecule drug discovery (Enki)
• Novel generative AI framework
• Delivers novel and selective leads
• Redefines the unit economics of drug discovery
• Moves beyond fixed screening libraries to explore uncharted regions of chemical space
• Simultaneously optimizes across 50+ parameters
• Cross-disciplinary team of machine learning researchers, chemists, and biotech professionals

Funding rounds we track

From the AI funding tracker — rounds as reported by the linked publications.